Rilvegostomig

AUG 14, 2026 · PHASE 3 TRIAL

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

ClinicalTrials.gov

This is a Phase 3 trial registration with no results posted; it describes a planned study of investigational therapy in advanced NSCLC, currently recruiting.

AUG 13, 2026 · PHASE 3 TRIAL

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

ClinicalTrials.gov

This is a clinical trial registry record describing a Phase 3 study that is currently recruiting with no results posted; it documents planned design and endpoints only.

AUG 12, 2026 · PHASE 3 TRIAL

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

ClinicalTrials.gov

This is a clinical trial registry record describing a planned Phase 3 study with no results posted; it documents design and enrollment targets only.